{
    "clinical_study": {
        "@rank": "153090", 
        "arm_group": [
            {
                "arm_group_label": "Zortress (Everolimus)", 
                "arm_group_type": "Active Comparator", 
                "description": "Zortress will be started on day of transplant and initially dosed at 0.75 mg twice a day (12 hours apart) dosed simultaneously with Neoral."
            }, 
            {
                "arm_group_label": "Rapamune (Sirolimus)", 
                "arm_group_type": "Active Comparator", 
                "description": "Rapamune will be dosed on day of transplant at 5 mg/d, decreasing to 3 mg/d."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being done to compare the effectiveness and safety of two different kidney\n      transplant immunosuppression drugs, Zortress (the study drug) and Rapamune (which is used in\n      the current standard immunosuppression regimen)."
        }, 
        "brief_title": "Comparing Everolimus and Sirolimus in Renal Transplant Recipients", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Renal Failure", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "detailed_description": {
            "textblock": "Zortress is FDA approved, is used as standard of care at some other institutions, and may\n      also be given as standard of care if it is believed to be the best immunosuppression regimen\n      for a particular kidney transplant recipient. The rationale for testing Zortress vs.\n      Rapamune is to determine which of these drugs is more effective in preventing chronic\n      rejection of the transplanted kidney.  Because these two drugs are related to each other\n      there is no current literature addressing the replacement of Rapamune with Zortress in an\n      immunosuppression regimen, therefore the goal of this study is to compare these two\n      immunosuppression drugs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients must give written informed consent before any assessment is performed.\n\n          2. Primary renal transplant recipients between ages 18 and 75 years of age.\n\n          3. Females capable of becoming pregnant must have a negative pregnancy test prior to\n             transplantation and practice an effective form of birth control for the duration of\n             the study and 12 weeks after discontinuation of the study drug if applicable.\n\n        Exclusion Criteria:\n\n          1. Total cholesterol > 300 mg/dl or triglycerides > 400 mg/dl despite lipid lowering\n             therapy\n\n          2. Pre-existing bone marrow suppression (White Blood Cell count of < 3000, platelets <\n             100,000)\n\n          3. Active infection (Hepatitis B Virus, HIV)\n\n          4. Malignancy (except for adequately treated squamous or basal cell skin carcinoma)\n             unless patient has written clearance from an Oncologist or if patient has had no\n             malignancy for at least 2 years prior to the transplant\n\n          5. Allergy or intolerance to Zortress, Rapamune, cyclosporine, or Anti-thymocyte\n             globulin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01976390", 
            "org_study_id": "2013H0229"
        }, 
        "intervention": [
            {
                "arm_group_label": "Zortress (Everolimus)", 
                "description": "0.75mg twice a day, Orally, starting on day of transplant", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug", 
                "other_name": "Zortress"
            }, 
            {
                "arm_group_label": "Rapamune (Sirolimus)", 
                "description": "5mg, Orally, starting on day of transplant; decreasing to 3mg", 
                "intervention_name": "Sirolimus", 
                "intervention_type": "Drug", 
                "other_name": "Rapamune"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antilymphocyte Serum", 
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Kidney", 
            "Kidney transplant", 
            "Renal failure", 
            "End Stage Renal Disease", 
            "kidney transplant recipient"
        ], 
        "lastchanged_date": "April 21, 2014", 
        "location": {
            "contact": {
                "email": "jerry.phalan@osumc.edu", 
                "last_name": "Jerry Phalan", 
                "phone": "614-293-4665"
            }, 
            "facility": {
                "address": {
                    "city": "Columbus", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "43212"
                }, 
                "name": "The Ohio State University Wexner Medical Center"
            }, 
            "investigator": {
                "last_name": "Ronald Pelletier, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Randomized, Single Center Pilot Study Comparing Patient and Graft Survival, Adverse Events and Tolerability of Zortress\u00ae (Everolimus) Versus Rapamune\u00ae (Sirolimus) in Combination With Low Dose Neoral\u00ae (Cyclosporine) Dosed by C2 Monitoring, in Deceased and Living Donor Renal Transplant Recipients Under a Thymoglobulin\u00ae (Antithymocyte Globulin) and Rapid Steroid Induction Protocol.", 
        "overall_contact": {
            "email": "jerry.phalan@osumc.edu", 
            "last_name": "Jerry Phalan", 
            "phone": "614-293-4665"
        }, 
        "overall_official": {
            "affiliation": "OSU Wexner Medical Center", 
            "last_name": "Ronald Pelletier, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this pilot study will be to determine equivalency of Zortress\u00ae as compared to Rapamune\u00ae when used in our de novo immunosuppression regimen following renal transplantation. The primary endpoint will be a composite endpoint of graft survival (non-death censored) and biopsy proven acute rejection at 1 year. The primary outcome of immunosuppressive protection would be studied in our Thymoglobulin and rapid steroid discontinuation protocol, with \"half-dose\" Neoral as described above.", 
            "measure": "Graft Survival Comparison of Zortress vs. Rapamune", 
            "safety_issue": "No", 
            "time_frame": "1 Year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01976390"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The Ohio State University", 
            "investigator_full_name": "Dr.Ronald Pelletier", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Ohio State University", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Dr.Ronald Pelletier", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}